Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026 in Las Vegas. Krish S. Krishnan, chairman and CEO, will join a fireside chat at 11:20 am PT and hold investor meetings the same day. A webcast will be available beginning at 11:20 am PT on the company’s Investors website.
Positive
- None.
Negative
- None.
News Market Reaction – KRYS
In the May 7 session, KRYS gained 2.67%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Earnings results | Positive | +7.9% | Strong 1Q 2026 revenue and cash position with updated guidance. |
| Apr 30 | Conference presentations | Neutral | +0.9% | Plans to present multiple gene therapy programs at scientific meetings. |
| Apr 21 | Earnings date notice | Neutral | -1.4% | Announcement of timing for 1Q 2026 results and conference call. |
| Feb 24 | Investor conference | Neutral | -2.8% | Participation in TD Cowen health care conference with fireside chat. |
| Feb 17 | Earnings results | Positive | +4.1% | Strong 4Q and FY2025 results and multiple regulatory milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings releases with strong fundamentals have seen positive price reactions, while conference and general news items have produced relatively modest moves, suggesting investors respond most to financial and pipeline detail.
Over the last several months, Krystal Biotech reported multiple positive earnings updates with VYJUVEK revenue growth and strong cash balances, notably on Feb 17, 2026 and May 4, 2026, each followed by positive price moves. Interim conference and presentation announcements, including events on Feb 24, 2026 and Apr 30, 2026, produced smaller reactions. Today’s BofA Securities conference participation fits this pattern as a visibility and engagement event rather than a major fundamental catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 13, 2026 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X.
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
